Nutriband's Trademark Triumph: A Boon for Abuse-Deterrent Pharmaceuticals

Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a pioneering developer of transdermal pharmaceutical products, has received a significant boost to its intellectual property portfolio with the Certificate of Registration for its trademark "Nutriband™." This registration, granted by the United States Patent and Trademark Office (USPTO) on February 18, 2025, covers Goods/Services in Class: 042, encompassing product research and development, scientific research and development, biochemical research and development, and pharmaceutical research and development. This strategic move strengthens Nutriband's brand identity and exclusivity in the transdermal pharmaceutical market, making it more challenging for competitors to mimic or copy the company's products and technologies.

The trademark registration for "Nutriband™" is integral to the commercialization of the company's platform technology, AVERSA, which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. By securing this trademark, Nutriband solidifies its competitive position in the market and enhances its ability to protect its intellectual property.

Nutriband's lead product under development, AVERSA™ Fentanyl, is an abuse deterrent fentanyl transdermal system that leverages the company's proprietary AVERSA™ technology. This product has the potential to reach peak annual U.S. sales of $80 million to $200 million, reflecting the significant impact that AVERSA™ technology could have on the market for abuse deterrent pharmaceutical products. According to a market analysis report by Health Advances, this substantial market potential underscores the strategic importance of Nutriband's trademark registration and its commitment to developing innovative, abuse-deterrent pharmaceutical products.

Nutriband's AVERSA™ abuse deterrent transdermal technology is designed to incorporate aversive agents into transdermal patches, deterring abuse by making the experience unpleasant. This technology is particularly relevant for drugs like fentanyl, which have a high potential for abuse. By ensuring that these essential medications remain accessible to patients who need them while enhancing their safety profiles, AVERSA™ technology addresses a critical unmet need in the market.

Nutriband's robust intellectual property portfolio, with patents granted in the United States and several other countries, further bolsters the company's competitive position. The AVERSA™ technology is supported by a comprehensive intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico, and Australia. This extensive protection enables Nutriband to license its technology to other pharmaceutical companies, generating additional revenue streams and expanding its market reach.

In conclusion, Nutriband's trademark registration for "Nutriband™" is a strategic triumph that enhances the company's intellectual property portfolio and competitive positioning in the transdermal pharmaceutical market. By securing this trademark, Nutriband solidifies its brand identity and exclusivity, further strengthening its commitment to developing innovative, abuse-deterrent pharmaceutical products. With the potential for AVERSA™ Fentanyl to reach peak annual U.S. sales of $80 million to $200 million, Nutriband is well-positioned to disrupt the market for abuse deterrent pharmaceutical products and generate significant value for its shareholders.